SCHEMBL3526653

SCHEMBL3526653

O=C(O)N1[C@@H]2CC[C@H]1CC(Nc1ncccc1[N+](=O)[O-])C2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.44
MAPT P10636 5/20 0.42
RAB9A P51151 3/20 0.42
NPC1 O15118 2/20 0.42
ALDH1A1 P00352 4/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
LMNA P02545 1/20 0.41
DPP4 P27487 1/20 0.40
DPP7 Q9UHL4 1/20 0.40
GPR119 Q8TDV5 1/20 0.39
NFKB1 P19838 1/20 0.39
MAPK1 P28482 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
PKM P14618 2/20 0.38
HTT P42858 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3526659 1.00 SMN1; SMN2 (0.44) SMN1; SMN2MAPTRAB9ANPC1ALDH1A1
SCHEMBL13543538 0.84 GPR119 (0.57) LMNAGPR119
SCHEMBL6887292 0.81 HTR3A (0.45) SMN1; SMN2MAPTRAB9ANPC1ALDH1A1
SCHEMBL6889512 0.81 HTR3A (0.45) SMN1; SMN2MAPTRAB9ANPC1ALDH1A1
SCHEMBL15204677 0.81 SMN1; SMN2 (0.48) SMN1; SMN2MAPTRAB9ANPC1ALDH1A1
SCHEMBL15204675 0.81 SMN1; SMN2 (0.48) SMN1; SMN2MAPTRAB9ANPC1ALDH1A1
SCHEMBL23236057 0.81 DPP4 (0.47) SMN1; SMN2MAPTRAB9ANPC1ALDH1A1
SCHEMBL1573866 0.81 MAPK1 (0.53) SMN1; SMN2MAPTRAB9ANPC1ALDH1A1
SCHEMBL7236134 0.81 MAPK1 (0.53) SMN1; SMN2MAPTRAB9ANPC1ALDH1A1
SCHEMBL1573863 0.81 MAPK1 (0.53) SMN1; SMN2MAPTRAB9ANPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7645771-B2 CCR5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORP. (US) 2010-01-12 US disclosed
US-20060229336-A1 Ccr5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORPORATION 2006-10-12 US disclosed
EP-1569646-A2 PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2005-09-07 EP disclosed
WO-2004054974-A2 PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2004-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229336-A1 Ccr5 antagonists as therapeutic agents CCR5, CCR1, CXCR3 SMN1; SMN2 4065/4885MAPT 4442/4885RAB9A 2633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.